PER-065-03已完成未知
A DOUBLE-BLIND, RANDOMIZED STUDY CONTROLLED WITH ACTIVE COMPARATOR MK-0767 AND METFFORMINA IN PATIENTS THAT SUFFER FROM DIABETES TYPE 2 INAPPROPRIATE CONTROL OF DIET AND EXERCISES.
MERCK & CO.INC.,0 个研究点目标入组 0 人开始时间: 2003年12月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 0（—）
入选标准
- •Between 21 and 78 years old.
- •Men and women not pregnant.
- •Understanding of the study procedures and agreement to participate in it, providing written informed consent.
- •Compliance with placebo treatment during the transition phase greater than or equal to 75%
排除标准
- •History of type 1 diabetes mellitus and / or history of ketoacidosis, peptide C <0.8 ng / mL (<0.26 nmol / L).
- •Patients requiring lipid-lowering agents, such as HMG-CoA reductase inhibitors (statins) other than open label simvastatin.
- •Patients requiring treatment with doses> 40 mg of simvastatin,> 20 mg / day of atorvastatin or equivalent doses of other HMG-CoA reductase inhibitors.
- •Patients under a regimen of estrogen replacement therapy or SERM (Selective Estrogen Receptor Modulator) who are expected to require significant adjustments of the regimen after Visit 1 / Week 9.
研究者
相似试验
已完成
不适用
A DOUBLE BLIND STUDY, RANDOMIZED, CONTROLLED WITH ACTIVE CONTROLLER, MULTICENTER, PARALLEL GROUP, TEST OF CONCEPT OF L-454560 IN PATIENT WITH COPD.PER-021-03MERCK SHARP & DOHME PERU S.R.L.,
已完成
不适用
RANDOMIZED, DOUBLE-BLIND STUDY, CONTROLLED WITH ACTIVE COMPARATOR, OF PARALLEL GROUPS, CARRIED OUT UNDER INTERNAL BLIND CONDITIONS TO EXAMINE THE SAFETY, TOLERABILITY AND EFFECTIVENESS OF 2 DOSE OF APPRENTICATOR IN THE PREVENTION OF NAUSEA AND POST-OPERATIVE VOMITINGPER-020-04MERCK SHARP & DOHME PERU S.R.L.,
进行中（未招募）
不适用
A STUDY OF THE MAINTENANCE OF EFFICACY OF ETANERCEPT PLUS DMARD(S)COMPARED WITH DMARD(S) ALONE IN SUBJECTS WITH RHEUMATOID ARTHRITIS AFTER ACHIEVING AN ADEQUATE RESPONSE WITHETANERCEPT PLUS DMARD(S)Rheumatoid ArthritisEUCTR2011-005448-87-HUPfizer Inc, 235 East 42nd Street, New York, NY 10017320
进行中（未招募）
不适用
A RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF THE MAINTENANCE OF EFFICACY OF ETANERCEPT PLUS DMARD(S)COMPARED WITH DMARD(S) ALONE IN SUBJECTS WITH RHEUMATOID ARTHRITIS AFTER ACHIEVING AN ADEQUATE RESPONSE WITHETANERCEPT PLUS DMARD(S)MedDRA version: 16.0Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid ArthritisEUCTR2011-005448-87-CZPfizer Inc, 235 East 42nd Street, New York, NY 10017320
进行中（未招募）
1 期
Estudio randomizado, doble ciego, controlado frente a placebo, prospectivo, multicéntrico, de búsqueda de dosis, en fase II/III, con atacicept subcutáneo en sujetos que recientemente han experimentado un brote de Lupus eritematoso sistémico.A randomised, double-blind, placebo-controlled, multicentre prospective dose-finding Phase II/III study with atacicept given subcutaneously to subjects having recently experienced a flare of systemic lupus erythematosus (SLE) - Atacicept in generalised SLE Phase II/IIIEUCTR2007-003698-13-ESMerck Serono International SA, An affiliate of Merck KGaA, Darmstadt, Germany